000131720 001__ 131720
000131720 005__ 20240229105009.0
000131720 0247_ $$2doi$$a10.1016/j.pnpbp.2017.05.019
000131720 0247_ $$2pmid$$apmid:28536069
000131720 0247_ $$2ISSN$$a0278-5846
000131720 0247_ $$2ISSN$$a1878-4216
000131720 0247_ $$2altmetric$$aaltmetric:20583380
000131720 037__ $$aDKFZ-2018-00026
000131720 041__ $$aeng
000131720 082__ $$a610
000131720 1001_ $$0P:(DE-He78)a9542bb104fe3f4d562e1d275e03f5ba$$aFeng, Weijun$$b0$$eFirst author
000131720 245__ $$aCRISPR-engineered genome editing for the next generation neurological disease modeling.
000131720 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2018
000131720 3367_ $$2DRIVER$$aarticle
000131720 3367_ $$2DataCite$$aOutput Types/Journal article
000131720 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1680173214_7807$$xReview Article
000131720 3367_ $$2BibTeX$$aARTICLE
000131720 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000131720 3367_ $$00$$2EndNote$$aJournal Article
000131720 500__ $$aDKFZ-ZMBH-Allianz
000131720 520__ $$aNeurological disorders often occur because of failure of proper brain development and/or appropriate maintenance of neuronal circuits. In order to understand roles of causative factors (e.g. genes, cell types) in disease development, generation of solid animal models has been one of straight-forward approaches. Recent next generation sequencing studies on human patient-derived clinical samples have identified various types of recurrent mutations in individual neurological diseases. While these discoveries have prompted us to evaluate impact of mutated genes on these neurological diseases, a feasible but flexible genome editing tool had remained to be developed. An advance of genome editing technology using the clustered regularly interspaced short palindromic repeats (CRISPR) with the CRISPR-associated protein (Cas) offers us a tremendous potential to create a variety of mutations in the cell, leading to 'next generation' disease models carrying disease-associated mutations. We will here review recent progress of CRISPR-based brain disease modeling studies and discuss future requirement to tackle current difficulties in usage of these technologies.
000131720 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000131720 588__ $$aDataset connected to CrossRef, PubMed,
000131720 7001_ $$0P:(DE-HGF)0$$aLiu, Hai-Kun$$b1
000131720 7001_ $$0P:(DE-He78)0ac2bd1a9fb1823a351ee4434d80808b$$aKawauchi, Daisuke$$b2$$eLast author
000131720 773__ $$0PERI:(DE-600)2008803-6$$a10.1016/j.pnpbp.2017.05.019$$gVol. 81, p. 459 - 467$$p459 - 467$$tProgress in neuro-psychopharmacology & biological psychiatry$$v81$$x0278-5846$$y2018
000131720 909CO $$ooai:inrepo02.dkfz.de:131720$$pVDB
000131720 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a9542bb104fe3f4d562e1d275e03f5ba$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000131720 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000131720 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0ac2bd1a9fb1823a351ee4434d80808b$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000131720 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000131720 9141_ $$y2018
000131720 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000131720 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bPROG NEURO-PSYCHOPH : 2015
000131720 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000131720 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000131720 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000131720 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000131720 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000131720 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000131720 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000131720 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000131720 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000131720 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000131720 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000131720 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000131720 9201_ $$0I:(DE-He78)A240-20160331$$kA240$$lA240 Molekulare Neurogenetik$$x0
000131720 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x1
000131720 980__ $$ajournal
000131720 980__ $$aVDB
000131720 980__ $$aI:(DE-He78)A240-20160331
000131720 980__ $$aI:(DE-He78)B062-20160331
000131720 980__ $$aUNRESTRICTED